GlassScriptPhysician profile
Steven D Macina
NPI 1124130471
$1,711.66
in general payments reported to CMS, 2019-2025
24 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2021: $639 · 2022: $35.49 · 2023: $267 · 2024: $16.91 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $363.39 | 2021-2023 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $237.20 | 2019-2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $231.29 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $203.34 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $168.88 | 2019-2024 | Rexulti |
| Abbvie INC. | $149.87 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.96 | 2021 | |
| Eisai INC. | $120.30 | 2021 | |
| Indivior INC. | $48.69 | 2023 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.50 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.54 | 2019 | |
| Lundbeck LLC | $11.70 | 2019 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Macina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.